
Dyne Therapeutics (DYN) Stock Forecast & Price Target
Dyne Therapeutics (DYN) Analyst Ratings
Bulls say
Dyne Therapeutics is attractive fundamentally because its FORCE platform is designed to solve one of the hardest problems in neuromuscular disease—delivering therapy to muscle and CNS—using TfR1-Fab-mediated delivery and indication-specific payloads. In DM1, DYNE-101 has shown pooled 12-month gains across vHOT, 5xSTS, QMT, and MDHI, plus movement across six CNS subscales, while safety remains encouraging with 143 patient-years and no related serious TEAEs. The thesis is further strengthened by DYNE-251’s ~10x dystrophin levels versus SOC in DMD, and by HARMONIA’s 150-patient, 48-week design that targets functional endpoints more aligned with real-world benefit.
Bears say
Dyne Therapeutics is viewed negatively because the DM1 program’s lead study, ACHIEVE-REC, carries materially lower-than-assumed statistical power after accounting for high placebo-arm variability, which cuts confidence in a clean readout and weakens the investment case. The company also chose to keep the trial small at N=71 despite Novartis’ larger N=159 failure, while the lack of individual-patient splicing data and weak linkage between splicing gains and vHOT benefit leave regulators and investors uncertain about true clinical translation. As a development-stage company with no revenue, continuing cash burn, and likely future debt or equity financing that could dilute holders, Dyne also faces meaningful financing and execution risk alongside safety, regulatory, and competition concerns.
This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Dyne Therapeutics (DYN) Analyst Forecast & Price Prediction
Start investing in Dyne Therapeutics (DYN)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Dyne Therapeutics (DYN) Forecast
Dyne Therapeutics (DYN) Analyst Forecast & Price Prediction
Start investing in Dyne Therapeutics (DYN)
Order type
Buy in
Order amount
Est. shares
0 shares